ESMO 2026 Breast Cancer Highlights: NATALEE, postMONARCH, TROPION-Breast02, INSPIRE-LM
From Oncology Brothers: Practice-Changing Cancer Discussions · · 24 min
This plays from the publisher's own server. We do not host a copy.
Description
Join us as we discussed the practice changing/informing studies presented at ESMO 2026. In this episode, we welcomed Dr. Javier Cortés, from Spain to discuss 4 key studies that are shaping the future of breast cancer treatment.
Episode Highlights:
- NATALEE: An update on adjuvant ribociclib for T2N0 with high-risk features and node-positive disease, including its impact on overall survival (OS) and distant disease-free survival (DDFS)
- postMONARCH: Insights into the use of abemaciclib after prior CDK4/6 inhibitors in metastatic hormone receptor–positive breast cancer, focusing on progression-free survival (PFS) and OS outcomes
- TROPION-Breast02: A look at the TNBC, highlighting the efficacy of datopotamab deruxtecan (Dato-DXd) in patients with central nervous system (CNS) metastasis
- INSPIRE-LM: Exploring the promising results of intrathecal trastuzumab and pertuzumab for patients with leptomeningeal disease in HER2-positive metastatic breast cancer
Tune in for an in-depth discussion on the latest advancements in breast cancer treatment and how these findings can be integrated into clinical practice.
Listen us on:
Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o
Follow us on social media:
- X/Twitter: https://x.com/oncbrothers
- Instagram: https://www.instagram.com/oncbrothers
- Website: https://oncbrothers.com/
Don't forget to like, subscribe, and hit the notification bell for more updates from the Oncology Brothers!
#BreastCancer, #ESMO2026, #CDK4-6i, #ADC, #OncologyBrothers
Back to Oncology Brothers: Practice-Changing Cancer Discussions · Report a problem